Standardized Shorter MDR-TB Regimen (SSR)
Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: Standard regimen including Moxifloxacin, Ethionamide, Pyrazinamide, Ethambutol, Clofazimine, and an injectable for 4-6 months
Effectiveness
75%
Safety Score
48%
Clinical Trials
20
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
Standard regimen including Moxifloxacin, Ethionamide, Pyrazinamide, Ethambutol, Clofazimine, and an injectable for 4-6 months
Time to Effect
1-2 months for culture conversion
Treatment Duration
9-12 months
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$4,000
Side Effect Mgmt:$3,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$19,231
Cost per Remission
$20,548
Comparison vs Conventional longer injectable MDR-TB regimen
Cost Difference
$-3,000/year
Less expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Standardized Shorter MDR-TB Regimen (SSR) Outcomes
for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+78%
Remission Rate
+73%
Common Side Effects
Hearing loss/vestibular toxicity (injectables)
+25%
Nephrotoxicity (injectables)
+12%
Gastrointestinal intolerance
+45%
QT prolongation
+20%
Hypothyroidism
+10%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov